Ursina Teitelbaum

University of Pennsylvania

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

University of Pennsylvania

Research Subjects

Research Interests

Ursina Teitelbaum has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

Charles Schneider
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
20 shared publications
Kim A. Reiss
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
20 shared publications
Mark H. O'HAra
University of Pennsylvania, Philadelphia, PA
20 shared publications
Thomas Benjamin Karasic
University of Pennsylvania 2 Abramson Cancer Center Philadelphia, Pennsylvania
20 shared publications
Arielle Yablonovitch
Guardant Health, Palo Alto, California
19 shared publications
Erica L. Carpenter
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
19 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Website
Google Scholar
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S2 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Open Access
Website
Google Scholar
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Patient-Level Data for Patients with Reversion Mutations
Website
Google Scholar
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S3 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Patient-Level Data for Patients with Reversion Mutations
Open Access
Website
Google Scholar
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
ROC and Test Characteristics from VAF Analysis with Binary Outcome of 12-month OS
Website
Google Scholar
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S4 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
ROC and Test Characteristics from VAF Analysis with Binary Outcome of 12-month OS
Open Access
Website
Google Scholar
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
VAF association with 12 month OS
Website
Google Scholar
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
VAF association with 12 month OS
Open Access
Website
Google Scholar
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Representativeness of Study Participants
Website
Google Scholar
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Representativeness of Study Participants
Open Access
Website
Google Scholar
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Website
Google Scholar
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S2 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Open Access
Website
Google Scholar
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Patient-Level Data for Patients with Reversion Mutations
Website
Google Scholar
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S3 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Patient-Level Data for Patients with Reversion Mutations
Open Access
Website
Google Scholar
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Website
Google Scholar
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S2 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Open Access
Website
Google Scholar
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
VAF association with 12 month OS
Website
Google Scholar
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
VAF association with 12 month OS
Open Access
Website
Google Scholar
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Representativeness of Study Participants
Website
Google Scholar
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib
by Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'HAra, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, et al.
Representativeness of Study Participants

Show all